Tag: Parp inhibitor

As part of an effort to enhance manufacturing efficiency, Pfizer has introduced a new soft gelatin capsule formulation for Talzenna (talazoparib). This modification maintains the medication's therapeutic properties. This raises the question: What is the new formulation of Talzenna, and how does this update impact individuals currently using the drug?

The FDA approved talazoparib, the generic name for Talzenna, for certain types of advanced breast cancer in 2018. Talzenna is a targeted therapy known as a PARP inhibitor, which is prescribed for specific cancers with particular genetic mutations. This article explains what is the generic name for Talzenna, its mechanism of action, and how it is used in cancer treatment.